Celcuity (CELC) Scheduled to Post Earnings on Thursday

Celcuity (NASDAQ:CELC) is scheduled to release its earnings data after the market closes on Thursday, November 14th. Analysts expect Celcuity to post earnings of ($0.65) per share for the quarter.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same quarter last year, the business posted ($0.66) EPS. On average, analysts expect Celcuity to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celcuity Stock Performance

Shares of CELC stock opened at $15.73 on Friday. Celcuity has a one year low of $10.16 and a one year high of $22.19. The company has a debt-to-equity ratio of 0.54, a quick ratio of 14.95 and a current ratio of 14.95. The company has a 50 day moving average price of $15.27 and a 200 day moving average price of $16.12. The firm has a market capitalization of $582.48 million, a price-to-earnings ratio of -5.74 and a beta of 0.76.

Wall Street Analysts Forecast Growth

CELC has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners began coverage on shares of Celcuity in a report on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Lifesci Capital started coverage on shares of Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price objective for the company. Finally, Stifel Nicolaus raised their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.